- About Us
- News & Events
- Get Information
- Our Research
- Treatment Trials
Esketamine for Depression
Pharmaceutical Trials in Depression
MAPrc's Psychopharmacology team conducts trials of new medications for treating depression in partnership with pharmaceutical companies who develop and manufacture cutting edge new medicines. These trials are randomised controlled trials (RCT's) and provide participants with access to the latest treatments for depression under controlled and safe conditions.
The aim of randomised controlled trials is to validate the effectiveness of new medicines for treating depression.
All randomised controlled trials (RCT's) have strict selection criteria to ensure the new medicine is trialled in specific subgroups of people, for example people with treatment resistent depression will require that the participant has trialled 2 or more existing treatments to be eligible to participate.
Trials of the new medicine are usually randomised against a comparator medicine that has already been shown to be effective, or against a placebo. Participants will visit our clinic for an initial screening visit, and then if eligible, for a randomisation visit where they will be commenced on the new medicine or it's comparator. Participants will attend our clinic each week for a check up and to complete assessments of the treatmente effectiveness. Saftey testing is also completed at each visit.
Participants are reimbursed between $30 - $40 for each visit to the clinic, and receive all medication free of charge.
To find out more about participating in one of our trials contact: firstname.lastname@example.org
International study to predict optimised treatment - in depression (iSpotD)
An international phase IV effectiveness trial to identify genetic, neurophysiological and cognitive markers that predict specific response to the three most widely prescribed anti-depressant medications (Lexapro, Zoloft and Effexor) in major depression.
This study is currently recruiting participants who have depression.
People with depression will be randomly allocated to receive one of three approved and effective treatments: escitalopram, sertraline or venlafaxine.
Participants are involved in the study for approximately 1 year (52 weeks). There are two clinic visits (at baseline and week 8) during which genetic, cognitive and electrical brain function assessments will be conducted. Further, participants are contacted via phone for check ups.
Ms. Mirjana Stojkovic
Recruitment for this study is now closed.